ADVENTRX (NYSE: ANX), a San Diego-based biopharmaceutical company, has made some strides in the development of a product candidate designed to treat genetic hematoma disorders, specifically sickle cell anemia (SCA), an orphan drug market with implications for millions of people.
September is Sickle Cell Awareness Month, a time when the medical community will gather with the patient population in the hopes of advancing research in this significant unmet medical need. One company, ADVENTRX Pharmaceuticals [NYSE: ANX], is attempting to engage the investor community and the sector’s most promising drug developers through the First Annual Sickle Cell Disease Therapeutics Conference, taking place September 19th, 2012 in New York City.
ADVENTRX and SynthRx, a private biotechnology company, completed a definitive merger on April 8, 2011.
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they have been successful in sending their ANX-530 (Exelbine) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011.
Copyright © 2024 | WordPress Theme by MH Themes